A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Inclusion Criteria

• •Diagnosed with ATTRv amyloidosis with polyneuropathy, with a documented V122I or T60A mutation
• •PND score of I-IIIB at baseline.
• •Exposure to commercial patisiran in one of the 3 cohorts:
• •* Prospective Cohort: Naive to patisiran treatment at the time of enrollment with intention to initiate treatment with patisiran.
• •* Mixed cohort: Currently on commercial patisiran therapy for less than 12 months at study enrollment.
• •* Retrospective cohort: Exposed to commercial patisiran treatment for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.